Guardant Health (GH) Common Equity (2017 - 2026)

Guardant Health has reported Common Equity for 10 years, with the latest figure at -$222.9 million in Q2 2026.

• Quarterly Common Equity rose 27.04% year-over-year to -$222.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$222.9 million (up 27.04% YoY) and the FY2025 annual result came in at -$99.3 million, up 28.89% from the prior year.
• Common Equity declined to -$222.9 million in Q2 2026 per GH's latest filing, from -$181.1 million in the prior quarter.
• Over five years, Common Equity peaked at $533.0 million in Q1 2022 and troughed at -$354.5 million in Q3 2025.
• A 5-year average of $9.3 million and a median of -$23.1 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 253.27% in 2024, then slumped 18838.31% in 2025.
• Over 5 years, Common Equity stood at $60.2 million in 2022, then jumped by 163.68% to $158.7 million in 2023, then plunged by 188.0% to -$139.6 million in 2024, then grew by 28.89% to -$99.3 million in 2025, then plunged by 124.42% to -$222.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$222.9 million, -$181.1 million, and -$99.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.